CD274 and familial pancreatic carcinoma: Similarly, Besaw et al. (33) reported a favourable response to anti-PD-L1 therapy in a patient with recurrent UC-OGCP, further supporting the clinical importance of immune modulation in managing this aggressive variant of pancreatic cancer.